Xiaosong Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2412125/publications.pdf

Version: 2024-02-01

92 papers	1,879 citations	430874 18 h-index	289244 40 g-index
100 all docs	100 docs citations	100 times ranked	3056 citing authors

#	Article	IF	Citations
1	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0152500.	2.5	219
2	Breast Cancer: Diffusion Kurtosis MR Imagingâ€"Diagnostic Accuracy and Correlation with Clinical-Pathologic Factors. Radiology, 2015, 277, 46-55.	7.3	196
3	Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nature Communications, 2019, 10, 4353.	12.8	193
4	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e115103.	2.5	182
5	Singleâ€cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Communications, 2020, 40, 329-344.	9.2	110
6	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. Biochemical Pharmacology, 2014, 87, 254-283.	4.4	100
7	Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer, 2013, 13, 390.	2.6	52
8	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumor Biology, 2016, 37, 9825-9835.	1.8	52
9	Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. Frontiers in Oncology, 2021, 11, 629666.	2.8	43
10	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33295-33304.	7.1	37
11	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. BMC Cancer, 2015, 15, 822.	2.6	34
12	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. Tumor Biology, 2016, 37, 4135-4142.	1.8	34
13	Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget, 2016, 7, 64182-64190.	1.8	34
14	Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget, 2016, 7, 31079-31087.	1.8	34
15	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget, 2017, 8, 38706-38716.	1.8	31
16	Measuring Î²â€tubulin III, Bclâ€2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Science, 2012, 103, 262-268.	3.9	23
17	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. International Journal of Biochemistry and Cell Biology, 2016, 71, 12-23.	2.8	22
18	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1877-1886.	2.5	21

#	Article	IF	Citations
19	Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. European Journal of Cancer, 2018, 89, 9-18.	2.8	20
20	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. World Journal of Surgical Oncology, 2019, 17, 37.	1.9	18
21	A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093267.	3.2	18
22	The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis. Oncotarget, 2018, 9, 11816-11823.	1.8	17
23	A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Translational Oncology, 2017, 10, 988-997.	3.7	16
24	Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. Integrative Cancer Therapies, 2017, 16, 406-413.	2.0	14
25	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. Scientific Reports, 2020, 10, 7029.	3.3	14
26	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. Scientific Reports, 2019, 9, 13123.	3.3	13
27	A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab . Cancer Management and Research, 2019, Volume 11, 3371-3379.	1.9	13
28	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. Annals of Surgical Oncology, 2019, 26, 2779-2786.	1.5	13
29	The Effects of Liver Transplantation in Children With Niemannâ€Pick Disease Type B. Liver Transplantation, 2019, 25, 1233-1240.	2.4	13
30	Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer. Breast, 2020, 49, 33-40.	2.2	13
31	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer, 2020, 20, 663.	2.6	13
32	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. Journal of Medical Internet Research, 2021, 23, e27576.	4.3	13
33	Association of tumorâ€infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Medicine, 2021, 10, 7921-7933.	2.8	12
34	Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. Breast Cancer Research and Treatment, 2020, 184, 193-202.	2.5	11
35	Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients. Breast, 2020, 52, 135-145.	2.2	11
36	IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 550.	2.8	11

#	Article	IF	Citations
37	Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer. Journal of Breast Cancer, 2019, 22, 399.	1.9	10
38	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. Breast, 2020, 54, 235-241.	2.2	10
39	A Decision Support System with Intelligent Recommendation for Multi-disciplinary Medical Treatment. ACM Transactions on Multimedia Computing, Communications and Applications, 2020, 16, 1-23.	4.3	10
40	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. Journal of Cancer, 2018, 9, 3216-3224.	2.5	9
41	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. Journal of Cancer, 2019, 10, 1110-1116.	2.5	9
42	Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists. Cancer Research, 2021, 81, 3105-3120.	0.9	9
43	Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 638619.	2.8	9
44	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. Journal of Cancer, 2020, 11, 6916-6924.	2.5	8
45	Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199667.	3.2	8
46	Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. Breast, 2021, 57, 71-79.	2.2	8
47	Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. Journal of Breast Cancer, 2018, 21, 277.	1.9	7
48	Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer. Frontiers in Oncology, 2020, 10, 1384.	2.8	7
49	A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer. Annals of Translational Medicine, 2021, 9, 367-367.	1.7	7
50	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?. Annals of Surgical Oncology, 2017, 24, 1874-1880.	1.5	6
51	Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes. Cancer Medicine, 2020, 9, 6173-6185.	2.8	6
52	Outcome of Liver Transplantation for Neonatal-onset Citrullinemia Type I. Transplantation, 2021, 105, 569-576.	1.0	6
53	CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646774.	3.7	6
54	Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. Journal of Geriatric Oncology, 2020, 11, 843-849.	1.0	5

#	Article	IF	Citations
55	Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women . OncoTargets and Therapy, 2020, Volume 13, 8027-8036.	2.0	5
56	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 619840.	2.8	5
57	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 222-230.	2.2	5
58	Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study. Cancer Research and Treatment, 2020, 52, 671-679.	3.0	5
59	Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. Frontiers in Oncology, 2021, 11, 636266.	2.8	4
60	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21â€‘gene recurrence score of 26â€‘30. Oncology Letters, 2020, 20, 1545-1556.	1.8	4
61	Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients. Frontiers in Oncology, 2022, 12, .	2.8	4
62	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 1315.	2.8	3
63	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50Âyears of age. Journal of Translational Medicine, 2021, 19, 75.	4.4	3
64	Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. Cancer Management and Research, 2021, Volume 13, 6279-6289.	1.9	3
65	Association of epithelial-mesenchymal transition with lapatinib resistance through multipe pathways activation in HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11579-e11579.	1.6	3
66	Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients. Frontiers in Oncology, 2021, 11, 763119.	2.8	3
67	A Multi-disciplinary Medical Treatment Decision Support System with intelligent treatment recommendation. , 2016, , .		2
68	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1335.	2.8	2
69	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. Frontiers in Oncology, 2020, 10, 708.	2.8	2
70	Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. British Journal of Cancer, 2021, 124, 975-981.	6.4	2
71	21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients. Frontiers in Endocrinology, 2021, 12, 725161.	3.5	2
72	Predictors of Nodal Pathological Complete Response in Asian Women with Stage IIâ€“III Node-Positive Breast Cancer. Oncology, 2021, 99, 359-364.	1.9	2

#	Article	IF	Citations
73	Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. Scientific Reports, 2022, 12, 2169.	3.3	2
74	Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score. Journal of Cancer, 2020, 11, 2509-2517.	2.5	1
75	Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. OncoTargets and Therapy, 2021, Volume 14, 3611-3624.	2.0	1
76	Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. Clinical Breast Cancer, 2022, 22, e147-e156.	2.4	1
77	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. BMC Cancer, 2021, 21, 707.	2.6	1
78	Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients. BMC Cancer, 2021, 21, 807.	2.6	1
79	Effect of curcumin on lapatinib sensitivity and lapatinib resistance associated EMT and stem-like phenotype in HER2 positive breast cancer.. Journal of Clinical Oncology, 2015, 33, e11594-e11594.	1.6	1
80	ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management. Annals of Surgical Oncology, 2020, 27, 731-732.	1.5	0
81	Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients. Journal of Cancer, 2020, 11, 2602-2609.	2.5	0
82	Reply to Letter to Editor: â€œHER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?â€• Breast, 2021, 55, 137.	2.2	0
83	Abstract PS1-53: Does the axilla surgical management for limited sentinel lymph nodes involvement vary between total mastectomy and breast-conserving surgery. , 2021, , .		0
84	Abstract PS18-22: Association of molecular biomarkers heterogeneity and treatment pattern, disease outcomes in multifocal or multicentric breast cancer patients. , 2021, , .		0
85	Abstract PS4-28: Efficacy of adjuvant chemotherapy stratified by age and the 21 gene recurrence score in estrogen receptor positive breast cancer. , 2021, , .		0
86	Abstract PS9-10: Can composite risk model help clinicians make adjuvant ovary function suppression dicision for breast cancer patients. , 2021, , .		0
87	A New k-Nearest Neighbors Algorithm for Learning from Multiple Experts' Uncertain Decisions. , 2021, , .		0
88	Effect of cancer-associated fibroblasts on trastuzumab resistance by activating multiple pathways in HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11587-e11587.	1.6	0
89	Analysis of factors related to adjuvant chemotherapy decision in early breast cancer patients with intermediate recurrence score.. Journal of Clinical Oncology, 2017, 35, e12032-e12032.	1.6	0
90	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. American Journal of Cancer Research, 2021, 11, 6188-6199.	1.4	0

#	Article	IF	Citations
91	Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.. American Journal of Cancer Research, 2022, 12, 152-164.	1.4	0
92	Editorial: Metabolic Abnormalities and Breast Cancer: Challenges From Bench to Bedside. Frontiers in Oncology, 2022, 12, 890810.	2.8	0